Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

<p>Correlation between baseline TIM-3 and PD-L1 IHC expression based on (<b>A</b>) DCR (per RECIST v1.1) and (<b>B</b>) irDCR (per irRECIST). Pretreatment TIM-3 IHC expression based on (<b>C</b>) adenocarcinoma histology, (<b>D</b>) squamous cell...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Diwakar Davar (15023480) (author)
Autres auteurs:	Zeynep Eroglu (19276519) (author), Mohammed Milhem (16527976) (author), Carlos Becerra (22053822) (author), Martin Gutierrez (15360052) (author), Antoni Ribas (14837278) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Hailei Zhang (20634191) (author), Srimoyee Ghosh (22053025) (author), Niranjan Yanamandra (22053022) (author), Theo Borgovan (22053031) (author), Shyam Srivats (22053825) (author), Angela Waszak (22053034) (author), Arindam Dhar (15016280) (author), Patricia LoRusso (15134565) (author)
Publié:	2025
Sujets:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Immunotherapy Antibody immunotherapy Checkpoint blockade Lung Cancer Oncogenes & Tumor Suppressors PD-1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!